Australia - English - Department of Health (Therapeutic Goods Administration)

doterra australia pty ltd - curcumin, quantity: 7.89 mg; vitis vinifera, quantity: 5.2632 mg (equivalent: vitis vinifera, qty 631.58 mg; equivalent: procyanidins (of vitis vinifera), qty 5 mg); boswellia serrata, quantity: 76.92 mg (equivalent: boswellia serrata, qty 461.54 mg; equivalent: boswellic acid, qty 50 mg); ginkgo biloba, quantity: 200 microgram (equivalent: ginkgo biloba, qty 10 mg; equivalent: ginkgo flavonglycosides, qty 48 microgram; equivalent: ginkgolides and bilobalide, qty 12 microgram); zingiber officinale, quantity: 2.5 mg (equivalent: zingiber officinale, qty 50 mg); sesamum indicum, quantity: 5 mg (equivalent: sesamum indicum, qty 20 mg); bromelains, quantity: 4.17 mg; camellia sinensis, quantity: 9.04 mg (equivalent: camellia sinensis, qty 271.2 mg; equivalent: caffeine, qty 45.2 microgram; equivalent: catechins (of camellia sinensis), qty 7.5 mg); mentha x piperita, quantity: 2.5 mg (equivalent: mentha x piperita, qty 10 mg; equivalent: menthol, qty 0 mg); carum carvi, quantity: 2.5 mg (equivalent: carum carvi, qty 10 mg); quercetin dihydrate, quantity: 12.5 mg; scutellaria baicalensis, quantity: 44.12 mg (equivalent: scutellaria baicalensis, qty 573.53 mg); ubidecarenone, quantity: 12.5 mg; reynoutria japonica, quantity: 25 mg (equivalent: reynoutria japonica, qty 2.5 g; equivalent: resveratrol (of reynoutria japonica), qty 12.5 mg); acetyl levocarnitine hydrochloride, quantity: 29.48 mg; alpha lipoic acid, quantity: 25 mg; silybum marianum, quantity: 31.25 mg (equivalent: silybum marianum, qty 2.1875 g; equivalent: flavanolignans calculated as silybin, qty 25 mg); punica granatum, quantity: 15.63 mg (equivalent: punica granatum, qty 781.25 mg); pinus pinaster, quantity: 2.61 mg - capsule, hard - excipient ingredients: croscarmellose sodium; soy polysaccharide; purified water; calcium hydrogen phosphate dihydrate; carrageenan; potassium acetate; maltodextrin; microcrystalline cellulose; glucose monohydrate; colloidal anhydrous silica; hypromellose; magnesium stearate - antioxidant/reduce free radicals formed in the body ; maintain/support energy production ; maintain/support general health and wellbeing

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - phytomenadione, quantity: 15 microgram/ml; ergocalciferol, quantity: 0.5 microgram/ml; retinol palmitate, quantity: 194.1 microgram/ml; dl-alpha-tocopherol, quantity: 0.91 mg/ml - injection, concentrated - excipient ingredients: soya oil; egg lecithin; glycerol; water for injections; sodium hydroxide - vitalipid n adult is indicated as a supplement in complete intravenous nutrition to meet the daily requirements of the fat- soluble vitamins a, d2, e and k1.

Australia - English - Department of Health (Therapeutic Goods Administration)

mysekyo australia pty ltd - zinc oxide, quantity: 3.1 mg (equivalent: zinc, qty 2.5 mg); ferrous fumarate, quantity: 7.6 mg (equivalent: iron, qty 2.5 mg); nicotinamide, quantity: 7.5 mg; natural fish oil, quantity: 200 mg (equivalent: docosahexaenoic acid, qty 20 mg; equivalent: eicosapentaenoic acid, qty 32 mg); calcium pantothenate, quantity: 10 mg (equivalent: pantothenic acid, qty 9.2 mg); d-alpha-tocopherol, quantity: 16.79 mg (equivalent: d-alpha-tocopherol, qty 25 iu); colecalciferol, quantity: 2.5 microgram; ascorbic acid, quantity: 50 mg; pyridoxine hydrochloride, quantity: 12.5 mg (equivalent: pyridoxine, qty 10.3 mg); cyanocobalamin, quantity: 0.0125 mg; folic acid, quantity: 125 microgram; betacarotene, quantity: 0.75 mg; heavy magnesium oxide, quantity: 49.8 mg (equivalent: magnesium, qty 30 mg); potassium iodide, quantity: 8.57 microgram (equivalent: iodine, qty 6.6 microgram); calcium carbonate, quantity: 50 mg (equivalent: calcium, qty 20 mg); riboflavin, quantity: 7.5 mg; citrus bioflavonoids extract, quantity: 12.5 mg; thiamine nitrate, quantity: 7.5 mg - capsule, soft - excipient ingredients: gelatin; lecithin; calcium phosphate; purified water; yellow beeswax; hydrogenated vegetable oil; glycerol; mannitol; colour; vegetable oil; dl-alpha-tocopherol; soya oil - antioxidant/reduce free radicals formed in the body ; helps reduce/decrease free radical damage to body cells ; helps convert (state food) into energy ; maintain/support general health and wellbeing ; maintain/support hair health ; maintain/support nail health/strength/thickness ; maintain/support bone health ; maintain/support red blood cell health ; maintain/support blood health ; maintain/support cardiovascular system health ; maintain/support heart health ; maintain/support healthy immune system function ; maintain/support (state vitamin/mineral/nutrient) levels in the body ; maintain/support (state vitamin/mineral) within normal range ; maintain/support skin health

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

biotech laboratories (pty) ltd - capsules - see ingredients - each capsule contains indomethacin 25 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

biotech laboratories (pty) ltd - capsules - see ingredients - each capsule contains furosemide 40,0 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

biotech laboratories (pty) ltd - capsules - see ingredients - each capsule contains tamsulosin hydrochloride 0,4 mg

South Africa - English - South African Health Products Regulatory Authority (SAHPRA)

biotech laboratories (pty) ltd - injection - see ingredients - each 5,0 ml vial contains rocuronium bromide 50,0 mg

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - amoxicillin trihydrate -

Australia - English - Department of Health (Therapeutic Goods Administration)

alphapharm pty ltd - hydralazine hydrochloride, quantity: 25 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; colloidal anhydrous silica; magnesium stearate; sodium starch glycollate; disodium edetate; purified talc - this product accepted for registration as 'currently supplied' at the time of commencement of the act. variation to pregnancy statement in product information were approved as specified in the letter of 13 august 1992 from dr bijoy varma. indicated for the treatment of drug resistant, moderate to severe, hypertension. this drug is not a first line antihypertensive drug and is better used in combination with other therapy such as a sympatholytic agent and a diuretic. indications as at 28 november 2001 : hypertension (drug resistant, moderate to severe): as supplementary medication for use together with other antihypertensives such as "beta"-blockers and diuretics; the complementary mechanisms of action of such combined therapy enable the drugs to exert their antihypertensive effects at low doses; in addition, unwanted accompanying effects of the individual substances are either partially offset or even cancelled out.